algorithRx Receives $1.5M NIH Grant
Monday, May 19, 2014
algorithmRx, headquartered in Richmond, Virginia, has been awarded a nearly $1.5 million research grant from the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health (NIH) as part of the NIH’s Small Business Innovation Research (SBIR) program.
The grant will fund further research related to algorithmRx’s predictive healthcare
algorithm, aRx Statin Advisor, which is one in a suite of novel, patent-pending, healthcare algorithms designed to improve the medication management of common chronic health conditions. aRx Statin Advisor is an evidence-based clinical decision support system (CDSS) designed to assist clinicians in selecting the most effective statin and dose regimen for patients with high LDL-cholesterol (“LDL-C” or “bad cholesterol”).
High LDL-C is a major, modifiable risk factor for cardiovascular disease (CVD) which is the number one cause of death in the US. With seven different statins, each available in four or five different doses, and no evidence-based selection tool available,there is a low chance that the initial statin/dose combination chosen by a healthcare provider will achieve the patient's LDL-C goal. Factors that contribute to suboptimal treatment include adverse effects experienced by the patient and poor medication adherence, each of which can be reduced or eliminated by better matching the statin and dose with the individual.
According to Lenn Murrelle, PhD, Managing Partner of algorithmRx, “This new NHLBI/NIH funding will allow aRx Statin Advisor to progress to the next stage and will be the final step towards commercialization.”